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Introduction
Human retinal dystrophies (RD) are a group of disorders 
characterized by a primary and progressive loss of photo­
receptor cells leading to visual handicap. Monogenic RD 
are rare diseases. The most common form of the disease, 
retinitis  pigmentosa  (RP),  is  characterized  by  primary 
degeneration of rod photoreceptors and has an estimated 
prevalence of around 1 in 4,000 [1­4], although higher 
frequencies  have  been  reported  in  some  Asian  popu­
lations (1 in 930 in South India [5], and approximately 1 
in 1,000 in China [6]). RP constitutes 85 to 90% of RD 
cases.
The first symptoms of RP are retinal pigment on fundus 
examination, and night blindness, followed by progres­
sive loss in the peripheral visual field, eventually leading 
to  legal  blindness  after  several  decades.  The  clinical 
aspects  of  RP  are  shown  in  Table  1.  The  clinical 
presentation can be macular, cone or cone­rod dystrophy 
(CORD),  in  which  the  decrease  in  visual  acuity  pre­
dominates over the visual field loss, or it can be the only 
symptom. Cone dystrophy is an inherited ocular disorder 
characterized  by  the  loss  of  cone  cells,  which  are  the 
photoreceptors responsible for central and color vision. 
Typically, age of onset is early teens, but it can be very 
variable,  ranging  from  congenital  forms  of  the  disease 
(Leber’s congenital amaurosis (LCA)) to late­onset RD.
RP is usually non­syndromic (70 to 80%), but there are 
also more than 30 syndromic forms, involving multiple 
organs and pleiotropic effects, the most frequent being 
Usher syndrome (USH; approximately 15 to 20% of all RP 
cases).  USH  associates  RP  with  sensorineural  deafness 
and sometimes vestibular dysfunction. The second most 
common  syndromic  form  is  Bardet­Biedl  syndrome 
(BBS), which accounts for 20 to 25% of syndromic forms 
of RP or approximately 5% of cases of RP. Patients with 
BBS typically present with RP, obesity, polydactyly, renal 
abnormalities and mild mental retardation.
It is worth noting that USH and BBS are genetically as 
heterogeneous as isolated RP. To date, nine genes have 
been identified for USH and 14 for BBS. The existence of 
patients lacking mutations in any of the identified genes 
indicates that at least one more gene remains unidentified 
for both syndromes.
Other syndromic forms of RP include associations with 
hearing  loss  and  obesity  (Alström  syndrome),  dysmor­
phic face and kidney deficiency (Senior­Locken syndrome), 
and  metabolic  disorders  [7].  Table  2  shows  the  most 
common  disorders  involving  non­syndromic  and  syn­
dromic RP.
Patterns of inheritance in retinitis pigmentosa
Both RD and RP show great clinical and genetic hetero­
geneity, and they can be inherited as autosomal­recessive 
(ar),  autosomal­dominant  (ad)  or  X­linked  (xl)  traits. 
Other atypical inheritance patterns, such as mito  chon­
drial,  digenic,  triallelic  and  isodysomy,  have  also  been 
associated with some RP cases [8].
Almost  half  of  RP  cases  are  sporadic,  without  any 
history  of  RD  in  the  family.  Diverse  patterns  of 
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of RP and their families depending on the geographical 
origin, the sample size of the study and the methods for 
clinical  ascertainment.  A  reliable  estimate  for  the 
percentages of each inheritance pattern could be 15 to 
25% for autosomal­dominant RP (adRP), 35 to 50% for 
autosomal­recessive RP (arRP), 7 to 15% for X­linked RP 
(xlRP), and 25 to 60% for syndromic RP [9] (Table 3).
However,  well­known  genetic  phenomena  that  alter 
Mendelian  inheritance  have  also  been  observed  in  RP. 
Incomplete  penetrance  [10]  and  variable  expressivity 
have  been  reported  in  many  families  with  RP.  The 
literature  offers  many  examples  of  variable  degrees  of 
severity  of  RP  among  members  of  the  same  family 
carrying the same mutation [11]. In xlRP forms, female 
carriers sometimes present RP symptoms and can be as 
affected as male carriers. One explanation for this might 
be lyonization, that is, the random inactivation of one X 
chromosome in females to compensate for the double X 
gene  dose  during  early  developmental  stages.  The 
inactivation  of  the  X  chromosome  not  carrying  the 
mutation in a cell or cell population that will later develop 
into the retina could lead to an active mutated RP gene in 
the female carrier.
Genes involved in retinitis pigmentosa
The overwhelming pool of genetic data that has become 
available  since  the  identification  of  the  first  mutation 
associated  with  RP  in  humans  (a  proline  to  histidine 
change at amino acid position 23 in rhodopsin, reported 
by Dryja et al. in 1990 [12]) has revealed the genetics of 
RD to be extremely complex. Research into the molecular 
causes of RD has revealed the underlying disease genes 
for about 50% of cases, with more than 200 genetic loci 
described [13]. These genes are responsible not only for 
RP, but also for many other different clinical entities such 
as LCA, macular degeneration and CORD. To date, 26 
genes have been identified for arRP and 20 for adRP, and 
two genes on the X chromosome (xlRP). For a number of 
these genes, some mutations in the same gene lead to 
autosomal­dominant forms, while some other mutations 
lead to autosomal­recessive forms.
Different mutations in several genes lead to syndromic 
forms such as USH or isolated RP (USH2A gene) or non­
syndromic deafness (MYO7A, CH23, PCDH15, USH1C 
and USH1G), and mutations in the same gene can cause 
different  clinical  entities,  as  has  been  observed  for 
ABCA4, which is implicated in arRP, autosomal­recessive 
macular  dystrophies  (arMD)  and  autosomal­recessive 
CORD (arCORD). Furthermore, most of the mutations 
causing RP are exclusive to one or a few individuals or 
families.  Common  mutations  and  hot  spots  are  rare; 
therefore, there is a need for large and time­consuming 
mutation screenings to achieve a molecular diagnosis of 
RP in patients. In addition, there is no clear genotype­
phenotype  correlation  and,  in  many  cases,  relatives 
Table 1.Clinical signs of retinitis pigmentosa and cone-rod 
dystrophy
Clinical signs
Visual function  Impaired night vision (nyctalopia), myopia  
  (frequently), progressive loss of visual acuity
Visual field  Loss of peripheral vision in early stages, progressive  
  loss of central vision in later stages, ring scotoma,  
  tunnel vision
Eye fundus  Bone spicule deposits in peripheral retina,  
  attenuation of retinal vessels, waxy pallor of the optic 
   disc
Eye movement  Nistagmus
Electroretinogram  Diminution or abolishment of the a-waves and  
  b-waves
Table 2. Non-syndromic and syndromic retinal dystrophies 
and inheritance pattern
Retinal dystrophy  Inheritance
Non-syndromic 
  Retinitis pigmentosa  ad, ar, xl, digenic
  Cone or cone-rod dystrophy  ad, ar, xl
  Leber congenital amaurosis  Mainly ar, rarely ad
  Stargardt disease  Mainly ar, rarely ad
  Fundus flavimaculatus  ar
  Congenital stationary night blindness  ad, ar, xl
  North Carolina macular dystrophy  ad
  Sorsby’s macular dystrophy  ad
  Pattern macular dystrophy  ad
  Vitelliform macular dystrophy (Best’s disease)  ad (incomplete  
    penetrance)
  Choroideremia  xl
  X-linked retinoschisis  xl
  Gyrate atrophy  ar
Syndromic 
  Usher syndrome  ar
  Bardet-Biedl syndrome  ar, oligogenic
  Senior-Locken syndrome  ar
  Alport syndrome  xl
  Älmstron syndrome  ar
  Joubert Syndrome  ar
  Nephronophthisis  ar, oligogenic
  Cockayne syndrome  ar
  Refsum disease  ar
  Autosomal dominant cerebellar ataxia type 7  ad
  Norrie disease  xl
ad: autosomal dominant; ar: autosomal recessive; xl: X-linked.
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RP in terms of age of onset and severity.
Many genes and proteins are associated with RD. These 
proteins are involved in retinal functions, but they can 
also play other roles such as degradation of proteins in 
the retinal pigment epithelium, and ionic interchange or 
trafficking of molecules in the ribbon synapse of photo­
receptors.  Tables  4,  5,  6  and  7  summarize  the  genes 
involved in RD, their chromosomal locations and func­
tions, and the proteins they encode. The major pathways 
involved in pathogenesis of RP are discussed below.
Phototransduction
Phototransduction is the process through which photons 
are converted into electrical signals. It begins with the 
light­induced isomerization of the ligand of rhodopsin, 
which is 11­cis retinal, and the activation of rhodopsin. 
Rhodopsin  undergoes  a  change  in  conformation  upon 
photoexcitation and activates the G protein transducin. 
GDP­bound inactive transducin exchanges GDP for GTP, 
and GTP­bound active transducin increases the activity 
of  cGMP  phosphodiesterase.  The  result  is  decreased 
levels  of  cGMP  in  the  cytoplasm,  and  this  causes  the 
closing of cGMP­gated ion channels and leads to mem­
brane hyperpolarization. The recovery of the photo  trans­
duction process is carried out by the phosphorylation of 
rhodopsin  by  a  receptor­specific  kinase,  rhodopsin 
kinase. The phosphorylated photoactivated rhodopsin is 
bound  by  arrestin,  thereby  terminating  activity  of  the 
receptor in the signal transduction process. Mutations in 
the gene encoding rhodopsin (RHO) are responsible for 
adRP,  arRP  and  dominant  congenital  stationary  night 
blindness. Mutations in the genes for cGMP phospho­
diesterase alpha and beta subunits (PDE6A and PDE6B, 
respectively)  are  responsible  for  arRP  and  dominant 
congenital stationary night blindness. Mutations in the 
genes encoding the rod cGMP­gated channel alpha and 
beta subunits (GUCA1A and GUCA1B, respectively) are 
responsible for arRP, while arrestin (SAG) is involved in 
Oguchi  disease.  The  genes  encoding  guanylate  cyclase 
activating protein 1B (GUCA1B) and cone alpha subunit 
of cGMP phosphodiesterase (PDE6C) are responsible for 
dominant MD and arCORD, respectively.
Visual cycle
After isomerization and release from the opsin protein, all­
trans retinal is reduced to all­trans retinol, and it travels 
back to the retinal pigment epithelium to be ‘recharged’ . It 
is  first  esterified  by  lecithin  retinol  acyl  transferase  and 
then  converted  to  11­cis  retinol  by  RPE65.  Finally,  it  is 
oxidized to 11­cis retinal before traveling back to the rod 
outer  segment,  where  it  can  again  be  conjugated  to  an 
opsin to form a new functional rhodopsin. Many proteins 
involved in the chemical transformation and transport for 
retinoids are causative agents of RD. Mutations in the gene 
that  encodes  the  retinal  pigment  epithelium­specific 
65kDa  protein  (RPE65)  can  cause  arRP  or  autosomal­
recessive  LCA  (arLCA);  ABCA  encodes  a  retinal  ATP­
binding cassette transpor  ter, and mutations lead to a wide 
variety of clinical symptoms, including arRP, autosomal­
recessive Stargardt disease and arCORD; the gene IRBP1 
encodes the inter  photoreceptor retinoid binding protein 
and mutations cause arRP; LRAT encodes lecithin retinol 
acyltransferase  and  mutations  cause  arRP  and  arLCA. 
Mutations in up to 13 different genes involved in the visual 
cycle lead to different retinal degenerations, highlighting 
the  importance  of  this  biochemical  pathway  in  the 
physiology of vision.
Table 3. Geographical distribution of genetic types
Country and reference  Non-syndromic RP (n)  adRP (%)  arRP (%)  xlRP (%)  Syndromic RP (%)
Spain [55]  1,717  15  34  7  41 (3 unclassified)
France [56]  153  19  35  4.1  41.3
The Netherlands [57]  575  22.4  30.1  10.4  37.1
Switzerland [1]  153  9  90  1  -
Germany [58]  250  25.2  16.4  10  48.4
UK [59]  300  39  15  25  21
USA [60]  138  22  10  14  37
USA [61]  489  14.1  13.7  7  65.2
Japan [62]  1,091  2.1  40.1    43.2
Japan [63]  434  16.9  25.2  1.6  56.3
China [64]  150  13.3  67.3  2.7  16.7
South Africa [65]  63  21  15  10  54
USA [66]  68  6  13  7  74
adRP: autosomal-dominant retinitis pigmentosa; arRP: autosomal-recessive retinitis pigmentosa; RP: retinitis pigmentosa; xlRP: X-linked retinitis pigmentosa.
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Pathway  Genes causing retinal dystrophy  Phenotypes
Phototransduction  CNGA1, CNGB1, GUCA1B, RHO, PDE6A, PDE6B, PDE6C, SAG, CNGB3  adRP, arRP, adMD, dCSNB, Oguchi disease, arCORD
Visual cycle  ABCA4, RGR, RLBP1, BEST1, IRBP, RPE65, CA4, RDH12, IDH3B, ELOVL4,   adRP, arRP, arMD, adMD, arCORD, adCORD, coroid
  PITPNM3, GUCY2D  sclerosis, arLCA
Phagocytosis of rod outer   MERTK  arRP
segments
Retinal development  CRX, NRL, NR2E3, SEMA4A, RAX2, PROM1, TSPAN12, TULP1, OTX2  adRP, arRP, adLCA, arLCA, adCORD, adMD, FEVR
Ciliary structure  CEP290, RP1, USH2A, CRB1, RP2, RPGR, RPGRIP1, LCA5, OFD1, MYO7A,   adRP, arRP, xlRP, arLCA, JS, BBS, USH, xlCORD, xlCSNB, 
  USH1C, DFNB31, CDH23, PCDH15, USH1G, GPR98, BBS1-BBS10, TRIM32,   MKS, LGMD2H, MKKS
  BBS12, BBS13, AHI1  
Photoreceptor structure  RDS, ROM1, FSC2  adRP, digenic RP, adMD 
mRNA splicing  HPRP3, PRPF8, PRPF31, PAP1, TOPORS  adRP
Others  ASCC3L1, SPATA7,EYS, KLHL7, RD3, KCNV2, RIMS1, CACNA2D4, ADAM9,   adRP, arRP, arCOD, arLCA, adCORD, CORD, arCORD, JS
  CNNM4, TRPM1, CABP4, OFD1
adCORD: autosomal-dominant cone and rod dystrophy; adLCA: autosomal dominant Leber’s congenital amaurosis; adMD: autosomal-dominant macular dystrophy; 
adRP: autosomal-dominant retinitis pigmentosa; arCORD: autosomal-recessive cone and rod dystrophy; arCOD: autosomal recessive cone dystrophy; arLCA: 
autosomal-recessive Leber’s congenital amaurosis; arMD: autosomal-recessive macular dystrophy; arRP: autosomal-recessive retinitis pigmentosa; BBS: Bardet-Biedl 
syndrome; CORD: cone and rod dystrophy; dCSNB: dominant congenital stationary night blindness; FEVR: familial exhudative vitreoretinopathy; JS: Joubert syndrome; 
LGMD2H: limb and griddle muscular dystrophy type 2H; MD: macular degeneration; MKKS: McKusick-Kaufmann syndrome; MKS: Meckel-Gruber syndrome; RdCVF: 
rod-derived cone viability factor; RP: retinitis pigmentosa; USH: Usher syndrome; xlCORD: X-linked cone and rod dystrophy; xlCSNB: X-linked congenital stationary 
night blindness; xlRP: X-linked retinitis pigmentosa.
Table 5. Genes and proteins leading to retinal dystrophies involved in phototransduction, visual cycle and phagocytosis 
of rod outer segments
Gene  Location  Protein  Function  %  Type of RP 
CNGA1  4p12  rod cGMP-gated channel alpha subunit  Phototransduction  2.2  arRP
CNGB1  16q13  rod cGMP-gated channel beta subunit  Phototransduction    arRP
GUCA1B  6p21.1  guanylate cyclase activating protein 1B  Phototransduction    adRP, adMD
RHO  3q22.1  rhodopsin  Phototransduction  19-25  adRP, arRP, dCSNB 
PDE6A  5q33.1  cGMP phosphodiesterase alpha subunit  Phototransduction  4  arRP 
PDE6B  4q16.3  cGMP phosphodiesterase beta subunit  Phototransduction  4  arRP, dCSNB 
PDE6C  10q23.33  cone alpha subunit of cGMP phosphodiesterase  Phototransduction    arCOD 
SAG  2q37.1  arrestin  Phototransduction    arRP, Oguchi disease
CNGB3  8q21.3  cone cyclic nucleotide-gated cation channel beta 3 subunit  Phototransduction    arCOD 
ABCA4  1p22.1  ATP-binding cassette transporter - retinal  Visual cycle  2,9  arRP, arMD, arCORD
RGR  10q23.1  RPE-retinal G protein-coupled receptor  Visual cycle  0,5  arRP, coroid sclerosis
RLBP1  15q26.1  retinaldehyde-binding protein 1  Visual cycle    arRP 
BEST1  11q12.3  Bestrophin-1  Visual cycle    adMD (Best type) 
IRBP      Visual cycle    arRP 
RPE65  1p31.2  retinal pigment epithelium-specific 65 kDa protein  Visual cycle  2  arRP, arLCA
CA4  17q23.2  carbonic anhydrase IV  Visual cycle    adRP
RDH12  14q24.1  retinal dehydrogenase 12  Visual cycle  4  arRP 
IDH3B  20p13  NAD(+)-specific isocitrate dehydrogenase 3 beta  Visual cycle    arRP
ELOVL4  6q14.1  elongation of very long fatty acids protein  Visual cycle    adMD
PITPNM3  17p13.2  phosphatidylinositol transfer membrane-associated family member 3  Visual cycle    adCORD 
LRAT  4q32.1  lecithin retinol acyltransferase  Visual cycle  0,7  arRP, arLCA 
GUCY2D  17p13.22  retinal-specific guanylate cyclase 2D  visual cycle  21  arLCA, adCORD
MERTK  2q13  c-mer protooncogene receptor tyrosine kinase  Phagocytosis of ROS  0,6  arRP 
adCORD: autosomal-dominant cone and rod dystrophy; adMD: autosomal-dominant macular dystrophy; adRP: autosomal-dominant retinitis pigmentosa; arCORD: 
autosomal-recessive cone and rod dystrophy; arCOD: autosonal recessive cone dystrophy; arLCA: autosomal-recessive Leber’s congenital amaurosis; arMD: autosomal-
recessive macular dystrophy; arRP: autosomal-recessive retinitis pigmentosa; ROS: reactive oxygen species.
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The stacks of discs containing visual pigment molecules in 
the outer segments of the photoreceptors are con  stantly 
renewed. New discs are added at the base of the outer 
segment at the cilium, and old discs are displaced up the 
outer segment and engulfed by the apical processes of the 
pigment epithelium. They are then broken down by lysis. 
Photoreceptor outer­segment discs are phagocytosed by 
the  pigment  epithelium  in  a  diurnal  cycle.  Among  the 
different proteins involved in this process, only MERTK, 
the gene encoding c­mer proto­oncogene receptor tyro­
sine kinase, has been identified as causing arRP.
Table 6. Genes and proteins leading to retinal dystrophies involved in structure of photoreceptors and ciliary function
Gene  Location  Protein  Function  %  Type of RP 
CEP290  12q21.32  centrosomal protein 290 kDa  Structural: connecting cilium  21  arRP, arLCA, JS, BBS 
FSC2  17q25.3  Fascin 2  Structural    adRP 
RDS  6p21.2  Retinal degeneration slow-peripherin  Structural  9.5  adRP, adMD, RP digenic 
          with ROM1
ROM1  11q12.3  retinal outer segment membrane protein 1  Structural  2  RP digenic with RDS 
RP1  8q12.1  RP1 protein  Structural: photoreceptor trafficking  3.5  adRP, arRP 
TULP1  6p21.31  tubby-like protein 1  Retinal development  2  arRP, arLCA 
USH2A  1q41  usherin  Structural: photoreceptor trafficking   10  arRP, USH 
CRB1  1q31.3  crumbs homolog 1  Structural: extracellular matrix  6.5  arRP, arLCA
RP2  Xp11.23  XRP2 protein similar to human cofactor C  Structural: photoreceptor trafficking   15  xlRP 
RPGR  Xp14  retinitis pigmentosa GTPase regulator  Structural: photoreceptor trafficking  75  xlRP, xlCORD, xlCSNB 
RPGRIP1  14q11.2  RP GTPase regulator-interacting protein 1  Structural: photoreceptor trafficking    arLCA 
LCA5  6q14.1  Lebercilin  Structural: photoreceptor trafficking    arLCA 
OFD1  Xp22.2  oral-facial-digital syndrome 1 protein  Ciliary function    JS 
MYO7A  11q13.5  Myosin VIIA  Photoreceptor trafficking    USH 
USH1C  11p14-p15  harmonin  Structural: scaffolding    USH 
DFNB31  9q32-q34  whirlin  Structural: scaffolding    USH 
CDH23  10q21-q22  cadherin-23  Structural: cell-cell adhesion    USH 
PCDH15  10q21-q22  protocadherin-15  Structural: cell-cell adhesion    USH 
USH1G  17q24-q25  SANS  Structural: scaffolding    USH 
GPR98  5q14-q21  VLGR1  Structural: extracellular matrix    USH 
BBS1  11q13  BBS protein 1  Ciliary function    BBS 
BBS2  16q21.2  BBS protein 2  Ciliary function    BBS 
ARL6/BBS3  3q11.2  ADP-ribosylation factor-like 6  Ciliary function    BBS 
BBS4  15q24.1  BBS protein 4  Ciliary function    BBS 
BBS5  2q31.1  flagellar apparatus-basal body protein DKFZp7621194  Ciliary function    BBS 
MKKS/BBS6  20p12.1  McKusick-Kaufman syndrome protein  Ciliary function: chaperonine    BBS, MKKS 
BBS7  4q27  BBS protein 7  Ciliary function    BBS 
TTC8/BBS8  14q32.11  tetratricopeptide repeat domain 8  Ciliary function    BBS 
B1/BBS9  7p14.3  parathyroid hormone-responsive B1 protein  Ciliary function    BBS 
BBS10  12q21.2  BBS protein 10  Ciliary function: chaperonine    BBS 
TRIM32  9q33.1  tripartite motif-containing protein 32  Ciliary function    BBS, LGMD2H 
BBS12  4q27  BBS protein 12  Ciliary function: chaperonine    BBS 
MKS1/BBS13  17q22  FABB proteome-like protein  Ciliary function    BBS, MKS 
AHI1  6q23.3  Abelson helper integration site 1  Ciliary function    NPH 
adMD: autosomal-dominant macular dystrophy; adRP: autosomal-dominant retinitis pigmentosa; arLCA: autosomal-recessive Leber’s congenital amaurosis; arRP: 
autosomal-recessive retinitis pigmentosa; BBS: Bardet-Biedl syndrome; CORD: cone and rod dystrophy; JS: Joubert syndrome; LGMD2H: limb and griddle muscular 
dystrophy type 2H; MKKS: McKusick-Kaufmann syndrome; MKS: Meckel-Gruber syndrome; NPH: Nephrohophthisis;.RP: retinitis pigmentosa; USH: Usher syndrome; 
xlCORD: X-linked cone and rod dystrophy; xlCSNB: X-linked congenital stationary night blindness; xlRP: X-linked retinitis pigmentosa.
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Retinal cells are specialized neurons structured in layers. 
Their patterns of connectivity are crucial, and the correct 
development of these cells is essential for retinal function. 
This development is regulated by the precise expression 
of genes in the right cell type and at the right time, and 
this regulation is mediated by the synergistic/antagonistic 
action  of  a  limited  number  of  transcription  factors. 
Muta  tions  in  the  cone­rod  otx­like  photoreceptor 
homeo  box  transcription  factor  (encoded  by  the  gene 
CRX)  are  responsible  for  adRP,  adLCA,  arLCA  and 
adCORD; mutations in the neural retina leucine zipper 
(encoded by the gene NRL) can lead to adRP and arRP. 
Mutations in the gene encoding the tubby­like protein 1 
(TULP1) can cause recessive RP or LCA. RAX2 encodes 
the  retina  and  anterior  neural  fold  homeobox  2 
transcription  factor,  and  mutations  are  responsible  for 
CORD.  Mutations  in  NR2E3  encoding  the  nuclear 
receptor  subfamily  2  group  E3  cause  arRP  or  adRP. 
Table 7. Genes and proteins leading to retinal dystrophies involved in retinal development, mRNA splicing and other 
functions
Gene  Location  Protein  Function  %  Type of RP 
KCNV2  9p24.2  potasium channel subfamily V member 2  Ion interchange    arCOD 
IMPDH1  7q32.1  inosine monophosphate dehydrogenase 1  Nucleotide biosynthesis  2.5  adRP, adLCA 
CRX  19q13.32  cone-rod otx-like photoreceptor homeobox transcription factor  Retinal development  1  adRP, adLCA, 
arLCA, adCORD 
NRL  14q11.2  neural retina leucine zipper  Retinal development  0.7  adRP, arRP
NR2E3  15q23  nuclear receptor subfamily 2 group E3  Retinal development    arRP 
EYS  6q12  eyes shut/spacemaker (Drosophila) homolog  Unknown    arRP 
HPRP3  1q21.3  human homolog of yeast pre-mRNA splicing factor 3  mRNA splicing  1  adRP 
PRPF8  17p13.3  human homolog of yeast pre-mRNA splicing factor C8  mRNA splicing  3  adRP 
PRPF31  19q13.42  human homolog of yeast pre-mRNA splicing factor 31  mRNA splicing  8  adRP 
PROM1  4p15.32  Prominin  Photoreceptor discs development    adCORD, adMD 
SNRNP200  2q11.2  small nuclear ribonucleoprotein 200kDa  mRNA splicing    adRP 
KLHL7  7p15.3  kelch-like 7 protein (Drosophila)  Protein degradation    adRP 
TOPORS  9p21.1  topoisomerase I binding arginine/serine rich protein  mRNA splicing  1  adRP 
RD3  1q32.3  protein: RD3 protein  Unknown    arLCA 
RAX2  19p13.3  retina and anterior neural fold homeobox 2 transcription factor  Retina development    CORD
SEMA4A  1q22  Semaphorin 4A  Neuronal development    adCORD 
RIMS1  6p13  regulating synaptic membrane exocytosis protein   Ribbon synapse trafficking    adCORD 
CACNA2D4  12p13.33  calcium channel, voltage-dependent, alpha 2/delta subunit 4  Ribbon synapse trafficking    arCOD 
CERKL  2q31.3  ceramide kinase-like protein      arRP 
AIPL1  17q13.2  arylhydrocarbon-interacting receptor protein-like 1  Chaperone  3.4  arLCA, adCORD
PAP1  7p14.3  PIM-1 kinase  mRNA splicing    adRP 
ADAM9  8p11.23  ADAM metallopeptidase domain 9 (meltrin gamma) protein  Structural: adhesion molecule    CORD 
CNNM4  2q11.2  cyclin M4  Neural retina function    Jalili synd. 
TRPM1  15q13.3  transient receptor potential cation channel, subfamily M,   Light-evoked response of the inner retina  adCSNB
    member 1 (melastatin)
SPATA7  14q31.3  spermatogenesis associated protein 7  Unknown    arLCA, arRP
TSPAN12  7q31.31  tetraspanin 12  Retinal development    FEVR
OTX2  14q22.3  orthodenticle homeobox 2 protein  Retinal development    adLCA 
ASCC3L1  2q11.2  activating signal cointegrator 1 complex subunit 3-like 1  Unknown    adRP 
CABP4  11q13.1  calcium binding protein 4  Synapsis function    arCORD 
USH3A  3q21-q25  clarin-1  Ribbon synapse trafficking    USH 
adCORD: autosomal-dominant cone and rod dystrophy; adCSNB: autosomal dominant congenital stationary night blindness adLCA: autosomal dominant Leber’s 
congenital amaurosis; adMD: autosomal-dominant macular dystrophy; adRP: autosomal-dominant retinitis pigmentosa; arCOD: autosomal recessive cone dystrophy; 
arCORD: autosomal-recessive cone and rod dystrophy; arLCA: autosomal-recessive Leber’s congenital amaurosis; arRP: autosomal-recessive retinitis pigmentosa; 
CORD: cone and rod dystrophy; FEVR: familial exhudative vitreoretinopathy; RP: retinitis pigmentosa; USH: Usher syndrome.
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semaphorin  4A  (SEMA4A)  lead  to  adCORD.  OTX2 
(encoding orthodenticle homeobox 2 protein) mutations 
are associated with adLCA. Finally, defects in TSPAN12 
(tetraspanin  12)  are  associated  with  familial  exudative 
vitreoretinopathy.
Photoreceptor structure
Although the majority of RD phenotypes appear to result 
from defects at a single genetic locus, at least one form of 
RP  appears  to  require  co­inheritance  of  defects  in  the 
unlinked genes RDS, which encodes peripherin/RDS, and 
ROM1, which encodes retinal outer­segment membrane 
protein 1. These proteins are components of the poly­
peptide subunits of an oligomeric transmembrane protein 
complex,  which  is  present  at  photoreceptor  outer­seg­
ment disc rims and is essential for the correct incidence 
of light into the discs.
Another protein, fascin 2, encoded by FSC2, appears to 
play  a  role  in  the  assembly  or  stabilization  of  inner 
segment  and  calycal  process  actin  filament  bundles  in 
photoreceptors and probably regulates the inner segment 
actin cytoskeleton.
Ciliary structure and function
Photoreceptors have an inner segment that contains the 
cell organelles and an outer segment composed almost 
exclusively of optic discs. The connecting cilium connects 
the inner and outer segments. These discs are constantly 
renewed  and  a  high  number  of  molecules  must  travel 
from the inner segment to the outer segment through the 
connecting cilium. The development and architecture of 
the connecting cilium, the correct folding of the involved 
proteins  and  the  links  between  the  cilium  and  its 
surrounding region (calycal process, extracellular matrix) 
have  been  shown  to  be  essential  for  retinal  function. 
Furthermore, as cilia are specialized structures present in 
many other tissues, defects in the protein components of 
the cilia and chaperones involved in their development 
can cause not only isolated RD but also conditions that 
include RD among their symptoms, such as USH or BBS. 
Recently,  it  has  been  demonstrated  that  some  ciliary 
proteins act as positive or negative phenotypic modifiers 
on defects in other proteins. Some examples are: USH2A, 
which  encodes  the  large  extracellular  protein  usherin, 
and defects are responsible for arRP and USH; the genes 
USH1C  and  DFNB31,  which  encode  the  scaffolding 
proteins  harmonin  and  whirlin;  and  CDH23  and 
PCDH15,  which  encode  the  cell­cell  adhesion  proteins 
cadherin 23 and protocadherin 15, respectively.
mRNA splicing
Pre­mRNA splicing is a critical step in mammalian gene 
expression. Mutations in genes involved in the splicing 
processes  or  spliceosome  are  associated  with  a  wide 
range of human diseases, including those involving the 
retina.  Among  the  genes  involved  in  mRNA  splicing, 
mutations  in  PRPC8  (human  homolog  of  yeast  pre­
mRNA splicing factor C8), PRP31 (human homolog of 
yeast  pre­mRNA  splicing  factor  31),  HPRP3  (human 
homolog  of  yeast  pre­mRNA  splicing  factor  3),  PAP-1 
(PIM­1  kinase),  TOPORS  (topoisomerase­I­binding 
arginine/serine­rich  protein)  and  SNRNP200  (small 
nuclear ribonucleoprotein, 200 kDa) are associated with 
adRP  [14­18],  although  the  mechanisms  behind  the 
process remain unclear.
Other functions
Many other genes and proteins are associated with RD. 
These proteins have a wide spectrum of functions, such 
as  degradation  of  proteins  in  the  retinal  pigmented 
epithelium  (RPE),  ionic  interchange,  trafficking  of 
molecules in the ribbon synapse of photoreceptors and 
many others. In addition, the functions of some proteins 
that have been associated with RD are still unknown.
Molecular diagnosis in retinal dystrophies
The first step toward the diagnosis of RD at the molecular 
level is genotyping; this allows a more precise prognosis 
of the possible future clinical evolution of RD, and it can 
be  followed  by  genetic  counseling.  Moreover,  genetic 
testing is crucial for the inclusion in human gene­specific 
clinical trials aimed at photoreceptor rescue. However, 
genetic  and  phenotypic  heterogeneity  limit  mutation 
detection, rendering molecular diagnosis very complex. 
While  sequencing  remains  the  gold  standard,  this  is 
costly and time consuming, and so alternative diagnostic 
approaches have been recently implemented.
One such alternative diagnostic approach is the use of 
microarray platforms to detect RP mutations. The most 
widely  used  are  the  specific­disease  chips  for  different 
types of RD. They contain the previously identified muta­
tions on the responsible known genes Identification rates 
(identifying  at  least  one  disease­associated  mutation) 
depend on the geographical origin and ethnicity of the 
patient,  and  they  currently  stand  at  47  to  78%  for 
Stargardt disease [19­23], 28 to 40% for CORD [21, 23, 
24, 25], 28 to 46% for LCA [26,­30], 45% for USH 1, and 
26% for USH 2 [31, 32]. These represent inexpensive and 
rapid first­step genetic testing tools for patients with a 
specific RD diagnosis.
In  addition,  other  high­throughput  DNA  sequencing 
platforms  targeted  to  hundreds  of  genes  are  being 
developed.  They  have  been  designed  to  contain  either 
genes limited to exons [33] or full­length retinal disease 
genes, including introns, promoter regions or both [34]. 
Other chip­based co­segregation analyses for autosomal­
recessive forms and LCA have also been designed, but 
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members of the family, both healthy and affected [35, 36].
Indirect  genetic  tools  for  linkage  analysis  and/or 
homozygosity  mapping  are  also  being  used  for  RD 
genotyping,  mainly  for  research  purposes.  However, 
increasing availability and low costs have made homo­
zygosity mapping a particularly appealing approach for 
the molecular diagnosis of RD [37].
The  analytical  validity  of  these  procedures  has  been 
proved.  However,  their  clinical  validity  remains  to  be 
established for every ethnic group, specific array and type 
of retinal disease. Clinical applications are also somewhat 
limited  due  to  the  fact  that  many  RP  genes  are  still 
unknown, and mutations may lie outside of commonly 
tested regions.
Perspectives for future therapeutics
Currently,  optical  and  electronic  devices  are  the  only 
tools available to improve vision in some patients with 
RD.  In  the  majority  of  cases,  there  are  no  effective 
therapies  available  to  prevent,  stabilize  or  reverse 
monogenic RD.
A key goal in developing an effective therapy for RD is 
the understanding of its pathophysiology, and the identi­
fication of the molecular events and disease mechanisms 
occurring in the degenerative retina. Based on advances 
in  knowledge  about  these  processes,  several  novel 
therapeutic  strategies  are  currently  being  evaluated, 
includ  ing pharmacological treatments, gene therapy and 
cell therapy.
RD disorders are initiated by mutations that affect rod 
and/or  cone  photoreceptors  and  cause  subsequent 
degeneration  and  cellular  death.  Consequently,  thera­
peutic  strategies  are  focused  on  targeting  the  specific 
genetic  disorder  (gene  therapy),  slowing  or  stopping 
photoreceptor degeneration or apoptosis (growth factors 
or  calcium­blocker  applications,  vitamin  supplements, 
endogenous cone viability factors), or even the replace­
ment  of  lost  cells  (transplantation,  use  of  stem  or 
precursor cells).
Before  these  strategies  can  be  applied  to  humans, 
animal  models,  preclinical  studies  and  appropriately 
designed human clinical trials are needed to test different 
treatments and provide information on their safety and 
efficacy. According to the ClinicalTrials.gov database, 44 
interventional clinical trials for RP have been or are being 
carried out [38].
Pharmacological therapies
Developing an effective pharmacological therapy for RD 
must be based on the knowledge of the molecular events 
and major disease mechanisms and the extent to which 
they overlap. Current therapies target these pathogenic 
mechanisms.
Vitamin supplementation and chaperone treatments
Results from experimental effects on animal models [39] 
and a randomized controlled double­masked clinical trial 
[40] have suggested possible clinical benefits of vitamin A 
supplementation  in  RP.  However,  the  use  of  these 
supplements  in  other  genetic  forms  of  RD,  such  as 
ABCA4­related diseases (arRP, arCORD, and autosomal­
recessive Stargardt MD), may accelerate the accumulation 
of  toxic  lipofuscin  pigments  in  the  retinal  pigment 
epithelium, and thus worsen photoreceptor degeneration. 
As a result, avoidance of vitamin A supplementation is 
recommended for people with Stargardt disease.
Another viable approach to RP therapy is the use of 
pharmacological  chaperones  [41].  Pharmacological 
chaperones target protein structure, while chaperone 
inducers  (for  example,  geldanamycin,  radicicol  and 
17­AAG) and autophagy inducers (for example, rapa­
mycin)  stimulate  degradation,  manipulating  the 
cellular quality control machinery. Some studies have 
suggested  that  the  rod  opsin  chromophore  (11­cis 
retinal)  and  retinal  analogues  (for  example,  9­cis 
retinal)  can  act  as  pharmacological  chaperones, 
whereas rapamycin is effective against the toxic gain of 
function,  but  not  the  dominant­negative  effects  of 
mutant rod opsin [41].
Anti-apoptotic therapy and neuroprotection: endogenous 
cone viability factors and growth factors
The  key  goals  in  pharmacological  therapy  for  RD  are 
neuroprotection  and  the  inhibition  of  pro­apoptotic 
pathways, or the activation of endogenous anti­apoptotic 
signaling systems [42]. Neuroprotection of photoreceptor 
cells is primarily targeted at structural preservation, and 
also  preventing  loss  of  function.  The  neuroprotective 
factors  include  one  ‘survival’  factor  (rod­derived  cone 
viability factor (RdCVF)) and four different neurotrophic 
factors  (ciliary  neurotrophic  factor,  basic  fibroblast 
growth  factor,  brain­derived  neurotrophic  factor  and 
nerve growth factor) that delay rod degeneration in some 
animal models of RP [43].
RdCVF  is  a  protein  that  increases  cone  survival. 
Injections  of  this  protein  in  p.P23H  rats  induced  an 
increase in cone cell number and a further increase in the 
electroretinogram, indicating that RdCVF can not only 
rescue  cones  but  can  also  significantly  preserve  their 
function [44].
Ciliary  neurotrophic  factor  has  shown  efficacy  in 
different animal models, and has progressed to phase II/
III clinical trials in early­stage and late­stage RP [45]. It 
has been administered by encapsulated cell technology, 
which allows the controlled, continuous and long­term 
administration  of  protein  drugs  in  the  eye,  where  the 
therapeutic agents are needed, and does not subject the 
host to systemic exposure [46].
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Many RD­associated genes have been identified and their 
functions  elucidated.  Over  the  past  decade,  there  has 
been  a  substantial  effort  to  develop  gene  therapy  for 
inherited retinal degeneration, culminating in the recent 
initiation of clinical trials.
A  variety  of  monogenic  recessive  disorders  could  be 
amenable  to  treatment  by  gene  replacement  therapy 
through the delivery of healthy copies of the defective 
gene via replication­deficient viral vectors [47, 48]. Pre­
limi  nary results from three clinical trials indicate that the 
treatment of a form of LCA by gene therapy can be safe 
and  effective.  Phase  I  clinical  trials  of  gene  therapy 
targeting the gene RPE65 [49­51] are being conducted in 
three different medical centers: Moorfields Eye Hospital, 
UK [49], the Children’s Hospital of Philadelphia, USA, 
[51],  and  the  Universities  of  Pennsylvania  and  Florida, 
USA. [50],
For some autosomal­dominant forms of RP or LCA, in 
which  expression  of  a  mutant  allele  has  a  gain­of­
function  effect  on  photoreceptor  cells,  or  a  dominant­
negative  mechanism  or  a  combination  of  both,  gene 
therapy is likely to depend on efficient silencing of the 
mutated  allele  [52].  Gene­silencing  strategies  for  these 
conditions  include  RNA  interference  by  microRNA­
based  hairpins  (Prph2  animal  model),  short  hairpin 
RNAs (IMPDH1 gene murine model), RNA interference 
by  microRNA  combined  with  gene  replacement 
(transgenic  mouse  simulating  human  RHO­adRP),  and 
antisense oligonucleotide technologies.
Cell therapy
Adult  stem  cells  isolated  from  the  retinal  pigment 
epithelium  at  the  ciliary  body  margin  can  differentiate 
into  all  retinal  cell  types,  including  photoreceptors, 
bipolar cells and Müller glia. Animal experiments have 
shown that, in response to environmental cues, they can 
repopulate  damaged  retinas,  regrow  neuronal  axons, 
repair  higher  cortical  pathways,  and  restore  pupil 
reflexes,  light  responses  and  basic  pattern  recognition. 
When transplanted into a damaged retina, the progenitor 
cells integrate with the retina, forming a protective layer 
that preserves existing cells and increases photoreceptor 
density ­ that is, neurogenesis can be fostered by recruit­
ment of endogenous stem cells into damaged areas or by 
transplanted stem cells [53].
Clinical trials using human fetal neural retinal tissue 
and retinal pigment epithelium cells and adult stem cells 
are in progress. A phase I clinical trial to repair damaged 
retinas in 50 patients with RP and age­related macular 
degeneration  has  been  conducted  in  India.  Phase  I 
clinical trials to repair damaged retinas in patients with 
RP degeneration have been conducted using autologous 
stem  cells  derived  from  bone  marrow,  injected  either 
near  the  cornea  or  intravitreally  (ClinicalTrials.gov 
NCT01068561).  Preliminary  results  have  shown  visual 
improvement.
Additionally,  a  non­invasive  cell­based  therapy 
consisting  of  systemic  administration  of  pluripotent 
bone­marrow­derived mesenchymal stem cells to rescue 
vision and associated vascular pathology has been tested 
in an animal model for RP, resulting in preservation of 
both  rod  and  cone  photoreceptors  and  visual  function 
[54]. These results underscore the potential application of 
mesenchymal stem cells in treating retinal degeneration.
Concluding remarks
To date, more than 200 genes associated with RD have 
been  identified;  they  are  involved  in  many  different 
clinical  entities  such  as  RCA,  LCA,  USH,  CORD  and 
MD. The most surprising outcome of these findings is the 
exceptional  heterogeneity  involved:  a  high  number  of 
disease­causing  mutations  have  been  detected  in  most 
RD genes, mutations in many different genes can cause 
the  same  disease,  and  different  mutations  in  the  same 
gene may cause different diseases. This genetic hetero­
geneity underlies a high clinical variability, even among 
family members with the same mutation. The RD genes 
involve many different pathways, and expression ranges 
from very limited (for example, expressed in rod photo­
receptors only) to ubiquitous.
Gaining knowledge of the genetic causes and pathways 
involved  in  the  photoreceptor  degeneration  underlying 
these  disorders  is  the  first  step  in  implementing  the 
correct clinical management and a possible prevention or 
cure for the disease.
An  increasing  number  of  clinical  trials  are  exploring 
different therapeutic approaches with the aim of treating 
inherited  retinal  dystrophies.  Phenotypic  characteriza­
tion  and  genotyping  are  crucial  in  order  to  provide 
patients with potential personalized treatment. Further 
research into the mechanisms underlying photoreceptor 
degeneration and retinal cell apoptosis should also bring 
us  closer  to  the  goal  of  developing  efficient  and  safe 
therapies.
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